for OWC Pharmaceutical
Learn more about OWC Pharma
Follow up letter to Stockholders
OWC invites its stockholders to attend the Special Meeting on December 20, 2019, at 10:00 a.m., local time ,at the offices of Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C. at 666 Third Avenue , New York, New York 10017.
OWC and STENOCARE A/S have signed a strategic MoU
Israeli Medical Cannabis
To Our Shareholders
The last year was a critical year in which we laid the foundations for the sustainable success for our Company. We defined our strategy carefully and consolidated our positioning as a company which undertakes the research and development of fully validated medical products and pharmaceuticals based on cannabis.
Sublingual disintegrating tablet
OWC Pharma reports the successful production of its cannabinoid-enriched sublingual disintegrating tablet, specifically developed as smoking substitute.
Cannabis-based topical ointment
OWC Pharma reported that the first ever safety study of cannabis-based topical ointment, conducted at Shiba Academic Medical Center, is close to completion as the last healthy volunteer started the treatment three weeks ago. The study is expected to be completed by the end of December 2018.